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Summary 
Title: Cardiac Allograft Vasculopathy 
Author: Robin Hansson 
Cardiac allograft vasculopathy (CAV) is a disease characterized by endothelial dysfunction, intimal 
thickening of coronary arteries with subsequent ischaemia and failure of the transplanted heart. 
CAV is one of the major determinants of longterm survival in cardiac transplant patients with an 
incidence of 48% at 10 years. The disease evolves from a complex interplay between both 
immunological and non-immunological factors, some being ”classical” atherosclerotic risk factors. 
Clinical diagnosis can be very difficult since these patients present with atypical symptoms of 
myocardial ischemia, no angina because of graft denervation, or often no symptoms at all. Instead 
the initial presentation is often progressive heart failure or sudden death making screening methods 
vital to detect the disease early. The standardized diagnostic and screening tool for the clinical 
practice is currently coronary angiography, although positive predictive value is only 44% when 
compared to intravascular ultrasound as the gold standard. Another a major disadvantage of 
angiography is the risk of developing contrast nephropathy since many of these patients have renal 
dysfunction from immunosuppressive treatment. While CAV generally is a slowly progressive 
disease, effective prevention and treatment methods are lacking and hence the disease carries a poor 
prognosis. Statins and mTOR inhibitors are key players in both prevention and treatment and are 
part of the standard drug regime for all patients. In addition to medical treatment, revascularization 
therapy is also possible in a very small subgroup of patients. However, revascularization is 
considered palliative and is not proven to prolong graft survival. Implantable cardioverter-
defibrillator (ICD) devices are used in advanced stages but is not evidence-based for CAV in 
particular. Unfortunately the only definite and ultimate treatment option is retransplantation. New 
treatment methods are clearly needed.     
Keywords: Coronary Artery Disease ￭ Heart Transplantation ￭ Immunology ￭ Inflammation 
￭ Microcirculation 
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Sažetak 
Naslov: Vaskulopatija Srčanog Presadka 
Autor: Robin Hansson 
Vaskulopatija srčanog presadka (VSP) je bolest karakterizirana disfunkcijom endotela, 
zadebljanjem intime koronarnih arterija sa posljedičnom ishemijom i zatajivanjem transplantiranog 
srca. VSP je jedna od glavnih determinanata dugoročnog preživljavanja u srčanih transplantiranih 
bolesnika sa učestalosti od 48% nakon 10 godina. Bolest se razvija iz složenih međudjelovanja 
između imunoloških i neimunoloških faktora, od kojih su neki “klasični” faktori aterosklerotskog 
rizika. Klinička dijagnoza može biti vrlo zahtjevna jer se ovi bolesnici prezentiraju sa atipičnim 
simptomima ishemije miokarda, bez angine zbog denervacije presadka, ili su često potpuno bez 
simptoma. Progresivno popuštanje presatka ili iznenadna smrt su nerijetko prve manifestacije ove 
bolesti, učinivši metode probira bitnima u ranom otkrivanju bolesti. Standardni alat u dijagnostici i 
probiru u kliničkoj praksi je trenutno koronarna angiografija, makar joj je pozitivna prediktivna 
vrijednost samo 44% kada se usporedi sa intravaskularnim ultrazvukom kao zlatnim standardom. 
Još jedna nepovoljna osobina angiografije je rizik od razvoja kontrastne nefropatije s obzirom da 
mnogo ovih pacijenata ima renalnu disfunkciju zbog imunosupresivne terapije. Iako je VSP 
generalno sporo progredirajuća bolest, nedostaju učinkovite metode prevencije i liječenja te je zbog 
toga bolest povezana sa lošom prognozom. Statini i inhibitori mTOR-a su za sada ključni u 
prevenciji i liječenju te su dio standardnog režima lijekova za sve pacijente. Uz lijekove, terapija 
revaskularizacijom je također moguća u relativno maloj podgrupi bolesnika. Međutim, 
revaskularizacija se smatra palijativnom metodom te nije dokazano da produžuje preživljavanje 
presadka. Implantabilni kardioverter-defibrilator (ICD) se često koristi u uznapredovalim stadijima 
VSP, iako bez koristi utemeljene dokazima. Nažalost, jedina preostala definitivna opcija liječenja 
jest ponovna transplantacija. Više je nego očito da trebamo nove i učinkovitije metode liječenja.     
Ključne riječi: Bolest Koronarnih Arterija ￭ Transplantacija srca ￭ Imunologija ￭ Upala ￭ 
Mikrocirkulacija  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1.0 Introduction 
Cardiac transplantation (HTx) is the gold standard treatment of advanced heart failure refractory to 
medical treatment, whereof non-ischemic cardiomyopathy is the most common diagnosis of the 
recipient. A total number of 4746 adult and pediatric heart transplants, including 589 combined 
heart and lung transplants, was registered in year 2014 to the International Society of Heart and 
Lung Transplantation (ISHLT). However it’s estimated that the total HTx number worldwide likely 
exceeds 5000 per year. The typical global adult recipient based on ISHLT's data have a mean age of 
54 years, a median survival of 12 years and the major morbidities they are expected to suffer from 
are hypertension, renal dysfunction, hyperlipidaemia, diabetes mellitus and at last cardiac allograft 
vasculopathy.  At Rebro University Hospital around 20 HTx are performed annually.  1 2
Cardiac allograft vasculopathy (CAV), also known as transplant coronary artery disease or cardiac 
transplant vasculopathy, is a disease characterized by endothelial dysfunction, intimal thickening of 
coronary arteries and subsequent ischaemia and failure of the transplanted heart. Incidence of CAV 
detected by angiography is 8% at 1 year, 29% at 5 years, 48% at 10 years. The three leading causes 
of death in the first post-transplant year are graft failure, non-CMV infection and multiple organ 
failure. After 3 years however, the leading causes of death are graft failure, malignancy, CAV and 
renal failure. Hence CAV is one of the major morbidities and major determinants of longterm 
survival.  In order to classify CAV uniformly worldwide a standardized nomenclature was 3
formulated by the ISHLT in 2010 (Table 1). The nomenclature is based on visual angiographic 
findings together with measures of cardiac allograft function and does also have a prognostic 
value.  4
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2.0 Pathogenesis 
Endothelial dysfunction and intimal proliferation with narrowing of coronary vessels is the endpoint 
of CAV. It results from the complex interplay between immunological and non-immunological 
factors (Figure 1.). CAV has long been referred to as chronic rejection, which should be avoided 
since it does not take non-immunogenic factors into account. CAV has quite different pathological 
characteristics (Table 2) in comparison to ”classical” atherosclerotic cardiovascular disease (CVD) 
although some non-immunogenic factors are common to both disease entities. The CAV lesions 
have a diffuse and concentric nature and preferentially affects small and medium sized vessel 
compared to proximal and eccentric lesions seen in atherosclerotic CVD. Also coronary veins and 
intramyocardial vessel are more frequently involved in the former.  5
The endothelium represents a critical border between the donor’s and the recipient’s allogenic 
tissues. Much like border patrol it serves a meaningful purpose by protecting both sides from 
unwanted trafficking but as tension rises it becomes corrupt and adds to the problem; termed 
endothelial activation and/or dysfunction. Activation means increased expression of human 
leukocyte antigen (HLA) molecules, adhesion molecules and cytokines leading to matrix deposition 
and smooth muscle cell (SMC) proliferation. , , , , ,  This pro-inflammatory milieu and 6 7 8 9 10 11
procoagulant response leads to typical vascular changes seen in CAV.  
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Table 1. Recommended Nomenclature for Cardiac Allograft Vasculopathy
ISHLT CAV0 (Not significant): No detectable angiographic lesion 
ISHLT CAV1 (Mild ): Angiographic left main (LM) ︎<50%, or primary vessel with maximum lesion of ︎<70%, or any 
branch stenosis ︎<70% (including diffuse narrowing) without allograft dysfunction 
ISHLT CAV2 (Moderate): Angiographic LM < ︎50%; a single primary vessel ≥70%, or isolated branch stenosis ︎≥70% 
in branches of 2 systems, without allograft dysfunction 
ISHLT CAV3 (Severe): Angiographic LM ︎≥50%, or two or more primary vessels ≥ ︎70% stenosis, or isolated branch 
stenosis ︎≥70% in all 3 systems; or ISHLT CAV1 or CAV2 with allograft dysfunction (defined as LVEF ︎︎≤45% usually 
in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology (which is 
common but not specific; see text for definitions) 
Definitions 
a) A “Primary Vessel” denotes the proximal and Middle 33% of the left anterior descending artery, the left 
circumflex, the ramus and the dominant or co-dominant right coronary artery with the posterior descending and 
posterolateral branches. 
b) A “Secondary Branch Vessel” includes the distal 33% of the primary vessels or any segment within a large septal 
perforator, diagonals and obtuse marginal branches or any portion of a non-dominant right coronary artery. 
c) Restrictive cardiac allograft physiology is defined as symptomatic heart failure with echocardiographic E to A 
velocity ratio ︎>2 ( ︎>1.5 in children), shortened isovolumetric relaxation time ( ︎<60 msec), shortened deceleration time 
( ︎<150 msec), or restrictive hemodynamic values (Right Atrial Pressure ︎>12mmHg, Pulmonary Capillary Wedge 
Pressure ︎>25 mmHg, Cardiac Index <︎2 l/min/m2) 
Endothelial dysfunction strictly speaking means that the vessel is unable to dilate properly and has 
an increased resting tone. The principal cause is reduced nitric oxide, either from decreased 
production or increased consumption, though increased endothelin activity is also a contributing 
factor. ,  The term dysfunction is sometimes also used to describe ”activation” simultaneously, 12 13
putting all these abnormal endothelial behavior under one umbrella and this terminology will be 
used henceforth. 
Neovascularization of heart tissue is a topic highly debated whereof replacement of endothelial cell 
is one subtopic, which is large enough for the sake of this discussion. Current knowledge is that 
replacement of endothelial cells and vasculogenesis is contributed by circulating host endothelial 
progenitor cell (EPCs).  While Medawar’s hypothesis suggests that this is a sign of graft adaptation 14
it may however just be a sign of endothelial damage with ineffective repair mechanisms, for three 
reasons. First, endothelial progenitor cell (EPCs) are significantly decreased in the circulation and 
enriched in coronary arteries of patients with CAV.  Secondly, the significance of EPCs reparative 15
contribution is not thought to be substantial.  And finally, inflammation suppresses EPCs survival 16
and mobilization.  17
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Figure 1. Pathogenesis of Cardiac Allograft Vasculopathy. *DCs, Dendritic cells. Ab, Antibody. NK, Natural killer. I/
R, Ischemia/Reperfusion.
2.1 Immunological factors 
Immunological events seem to be of the greatest importance, after all CAV only develops in donor’s 
and not recipient’s arteries. There are a number of ways for host immune cells to recognize the graft 
as foreign. Donor dendritic cells (DCs) can present foreign major histocompatibility complex 
(MHC) to host T-cells, called the direct pathway.  Host DCs can internalize, process and present 18
donor peptides with their MHC, the indirect pathway.  A relatively novel discovery is that host 19
DCs can acquire donor MHC through cell-to-cell contact, named the semi-direct pathway.  Donor 20
endothelial cells can also present their MHC I, and later if activated MHC II as well, to host T-
cells.  It is though that the indirect pathway is responsible for both cardiac allograft vasculopathy 21
and chronic rejection.18,   22
Whatever the starting point may be, both the cellular and humoral arm are involved, with T- and B- 
cell activation and differentiation to CD8+ T-cells, CD4+ T-cells and specific antibodies. Studies 
have shown that HLA mismatching, HLA-DR in particular, have a greater incidence in recipients 
who develop CAV compared to those who do not.  Same applies for specific antibodies towards 23
HLA class I or class II, but also peptide-specific anti-endothelial antibodies. , ,  A temporal 24 25 26
relationship has been observed in the appearance of activated T-cells in cardiac grafts, with early 
predominance of cytotoxic/CD8+ T-cells and later helper/CD4+ T-cells in more advanced 
pathological stages. Endothelial cells, like all other nucleated cells, express their MHC class I from 
the very beginning and later expresses MHC class II when activated.  27
Several factors reflect the impact of systemic inflammation and the innate immune system’s 
involvement. The well known C-reactive protein (CRP), a marker of systemic inflammation, is an 
established predictor of CAV.  Increased gene expression of Toll-like receptor 4 (TLR-4) in 28
circulating monocytes is associated with CAV.  Presence of complement component 4d (C4d) in 29
endomyocardial biopsy is an independent risk factor.  Natural killer (NK) cells inflict CAV 30
independently from T- and B-cells  in concert with donor specific antibodies (DSA).  31
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Table 2. Differences between Cardiac Allograft Vasculopathy and Atherosclerotic Cardiovascular Disease
CAV Atherosclerotic CVD
Location 
Plaque type 
Inflammation 
Vasculitis 
Internal elastic lamina 
Calcium deposits
Distal 
Diffuse/Longitudinal, concentric 
Yes 
Infrequently 
Intact 
No
Proximal 
Focal, eccentric 
Rarely 
Never 
Disrupted 
Yes
A plenty of cytokines and adhesions molecules are found in CAV lesions. These include cytokines: 
IL-1, IL-6, TNF-α, PDGF, IGF-1, MCP-1, FBGF, VEGF, TGF-α, TGF-β-1 and IFN-𝛾. Adhesion 
molecules include: ICAM-1, VCAM-1, E-selectin and P-selectin. They mediate different 
pathological mechanism including leukocyte and platelet adhesion, chemoattraction of leukocytes, 
SMCs proliferation etc.7–11 The role of IFN-𝛾 is of particular interest since deficiency of this 
cytokine prevents CAV in mice models.  32
Lastly, increased frequency of moderate and severe cellular rejection episodes as well as total 
rejection score, correlates well with CAV suggesting that immunological events are of utmost 
importance in the pathogenesis of the disease. , , , ,  33 34 35 36 37
2.2 Non-immunological factors 
Non-immunological factors can be classified as recipient or donor associated. The most important 
recipient associated risk factors are components of the metabolic syndrome (central obesity, 
hypertension, diabetes, dyslipidemia) since they are very frequent, present either prior to HTx or as 
a result of immunosuppressive therapy (i.e. cyclosporine & corticosteroids). Lipid abnormalities are 
not merely a risk factors but also seem to correlate well with CAV severity. , ,  Patients with 38 39 40
either high glucose or high insulin concentrations have higher incidence of CAV and a reduced 
survival.  Insulin resistance has a synergistic effect with elevated CRP levels which is evident from 41
a fourfold increased risk of developing CAV when occurring together, highlighting the interplay 
between immunological and non-immunological events.  42
Cytomegalovirus infection (CMV) is another risk factor. CMV activates the immune system both 
directly and secondarily through endothelial assault causing endothelial dysfunction.  It's also 43
though that CMV infection has negative influence on vascular remodeling from observations of net 
lumen loss in infected patients.  44
Older age of the recipients is a protective factor while the opposite is true for donors. Male sex and 
older age are donor associated risk factors. ,  Age is one of the strongest predictors for 45 46
atherosclerotic CVD and indeed history of atherosclerotic CVD in the recipient or the donor are risk 
factors for CAV.46, ,  Surprisingly older donor age and/or history of CVD does not reduce survival 47 48
nor freedom from ischemic events.13,  Other donor associated risk factors are: explosive brain 49
death (e.g. head trauma and intracerebral hemorrhage) , , organ preservation damage , ischaemia-50 51 52
reperfusion injury43, DD genotype of ACE gene polymorphism  & hepatitis C virus 53
seropositivity .54
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Miscellaneous risk factors are hyperhomocysteinemia , increased elastase activity , 55 56
thrombospondin-1 , expression of tissue factor and the vitronectin receptor . The exact role of 57 58
fibrinolysis is still under scrutiny. On one hand animal models suggest that plasminogen system 
contributes to CAV as mentioned earlier. In contrast, tissue-type plasminogen activator (tPA) 
depletion and plasminogen activator inhibitor-1 (PAI-1) expression in human cardiac grafts are 
much more related to CAV (78% vs 24%) and their carriers are much more likely to die or need a 
second HTx (30% vs. 2.5%). ,  59 60
3.0 Diagnosis & Screening 
Detecting CAV is truly a challenge. Foremost, clinical symptoms are often absent or atypical. When 
early symptoms do appear, patients seldom present with angina pectoris (because of graft 
denervation) or premonitory symptoms at exertion. The most common symptoms according to a 
study of 22 HTx patients were angina equivalents such as weakness and dyspnea that led to 
misdiagnosis of infection or congestive heart failure (HF) at admission.  Also electrocardiogram 61
(ECG) is of limited value because of the high prevalence of electrocardiographic abnormalities in 
this population of patients.  When early symptoms are absent, the initial presentation of CAV is 62
often progressive HF or sudden death. Therefore, effective screening methods are warranted in 
order to detect the disease in early stages and to improve it's outcome. The general screening 
schedule for a post HTx patient at Rebro University Hospital can be seen in Table 3. 
3.1 IVUS 
Intravascular ultrasound (IVUS) is the most sensitive method in diagnosing CAV. Hence, IVUS is 
used in many large multicenter studies to assess drug efficacy in treatment and prevention of CAV. 
It is also used in clinical practice when other diagnostic methods fail to explain the reason for graft 
failure. Unlike coronary angiography which only visualizes the vessel lumen, IVUS also inspects 
tunica intima and media of the vessel wall. Through serial observations it’s seen that the most rapid 
rate of intimal proliferation occurs during the first post-transplant year. Should the intimal 
thickening be ≥0.5mm in that period of time it’s defined as rapidly progressive, which is associated 
with more frequent deaths, graft loss and nonfatal major adverse cardiac events (45.8% vs. 
16.8%).  Risks of procedure complications are low in experienced hands, with reports showing 63
complications of 1.6% when performing multi vessel IVUS.  IVUS is unfortunately a very costly 64
and time-consuming tool. So despite IVUS's high positive predictive value (PPV) and low risk of 
complications, it is not recommended for routine surveillance in the clinical practice.4 
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3.2 Coronary angiography 
Coronary angiography (Figure 2. & Figure 3.) is the standard method for surveillance and 
monitoring of CAV.4 A baseline examination is performed at around 4 weeks post-transplant and 
then biannually, annually or every other year there after (Table 3.) depending on each center’s 
preferences. More frequent examinations may be indicated if signs of graft failure through other 
diagnostic methods are present, e.g abnormal ventricular wall motion visualized on 
echocardiography. Coronary angiography can only assess  luminal diameter and the contrast-filling 
time. This makes it very hard to spot CAV lesions early since the lesions are concentric, 
longitudinal and diffuse. Hence, the PPV of coronary angiography is only 44% compared to IVUS 
as the gold standard.  To avoid false diagnosis of CAV from  vasospasm, an intracoronary 65
vasodilator such as nitroglycerine should be administered prior to contrast. A paradoxical  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*mo, months. DSA, donor specific-antibody. Angio, coronary angiography. Echo, echocardiography. 6MWT, six-
minute walk test. ♰For scientific purposes. 
Table 3. Screening schedule for post HTx patients at Rebro University Hospital.
Biopsy 
(cellular)
Biopsy 
(humoral)
DSA*♰ Angio* Echo* 6MWT*♰ Holter♰
1 mo + + + + + + +
2 mo + + + +
4 mo + + + +
6 mo + + + + + +
9 mo + +
1 year + + + + + + +
16 mo + +
20 mo + + + +
2 years + + + + + +
30 mo + + + +
3 years + + + + + + +
4 years + + + + + +
5 years + + + + + + +
7 years + + + + + + +
10 years + + + + + + +
vasoconstrictive response towards the vasodilator signifies endothelial dysfunction and is 
significantly associated with higher incidence of angiographic vasculopathy at 1 year (58% vs. 
13%).   66
To attain the contrast-filling time, TIMI (thrombolysis in myocardial infarction) frame count is 
used. TIMI frame count is the number of cine frames required for dye to reach distal coronary 
landmarks during coronary angiography and it may very well correlate with CAV, though 
conflicting result have emerged from different studies. ,  Two additional measures that rely on the 67 68
angiographic wire are coronary flow reserve (CFR) and optical coherence tomography. In order to 
measure CFR a doppler ultrasound transducer is located at the tip of the wire, thus the velocity of 
coronary blood flow can be measured. CFR is the increase of flow in response to a intracoronary 
vasodilator, and is found be reduced in patients with proven CAV.  Optical coherence tomography 69
is a novel method that seems to be very sensitive in detecting early CAV but further research is 
needed to determine its definite its role.  A major drawback of angiography is the risk of contrast 70
induced nephropathy, since HTx patients sooner or later develop renal dysfunction from 
immunosuppressive therapy. 
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Figure 2. Coronary angiography showing diffuse 
stenosis of the left anterior descending artery and distal 
pruning of left circumflex artery in a patient with CAV. 
Figure 3. Coronary angiography showing severe 
stenosis of mid-left anterior descending artery with 
some diffuse irregularities on both left anterior 
descending and left circumflex arteries in a patient with 
CAV. 
3.3 Endomyocardial biopsy 
Except for being part of routine allograft rejection surveillance, endomyocardial biopsy can also 
diagnose CAV. As stated earlier, endothelial dysfunction is the endpoint in the pathogenesis of the 
disease. Demonstrating endothelial dysfunction through immunohistochemistry can therefore 
predict CAV before angiographic changes are noticed. In a study of 121 HTx patients, specimens 
demonstrated presence for ICAM-1 and HLA-DR (markers of endothelial dysfunction) in 78 
patients within the first 3 months post-transplant. This group had a significant higher risk and 
progression rate for developing angiographic CAV compared to the 43 patients with negative 
specimens.  Simple histological evaluation of microvasculopathy is not as useful in predicting 71
CAV. While it’s postulated that microvasculopathy is a prognostic factor CAV some studies are 
skeptical. , ,  Heimann et al did however find stenotic microvasculopathy to be a risk factor for 72 73 74
three-vessel epicardial disease and a predictor of long-term survival after HTx.   75
A major disadvantage of endomyocardial biopsy is its low sensitivity when compared to IVUS or 
angiography. This is presumably because of the low probability of obtaining a sample with 
microvasculature. 
3.4 Noninvasive investigations 
Because of several disadvantages of angiography (i.e patient discomfort, radiation and use of 
contrast agents) other potential techniques are being explored. The best validated noninvasive 
technique for the moment is dobutamine stress echocardiography. According to a study of 109 HTx 
recipients the sensitivity was 85% when compared to angiography and IVUS combined as the gold 
standard, and the negative predict value (NPV) was excellent.  Although later studies have not 76
been able to reproduce such a high sensitivity and NPV (one large study of 497 patients showing 
only 7% and 41% respectively) , stress echocardiography is still recommended as part of general 77
CAV screening and as a substitute for a selected patient group, i.e. patients at low risk (with no 
signs of CAV on angiography/IVUS at five years) or/and with advanced renal disease (eGFR < 30 
to 40 mL/min/1.73 m2) at risk of developing contrast nephropathy. Results however should always 
be interpreted with caution and coronary angiography should be performed if CAV is suspected.  
Other noninvasive investigation methods are coronary computed tomography angiography (CCTA), 
cardiovascular magnetic resonance (CMR), positron emission tomography (PET), CFR by 
echocardiogram and biomarkers. 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A meta-analysis in year 2014 concluded that 64-slice CCTA is a reliable alternative to coronary 
angiography with sensitivity and NPV of both 97%, when compared to coronary angiography as a 
gold standard.  Unfortunately, major disadvantages keep this method from being recommended as 78
a standard noninvasive screening tool such as high burden of radiation, increased risk of 
nephrotoxicity from the greater amount of contrast needed, difficulties in detection of distal and 
small vessel disease and the high prevalence of tachycardia in these patients. ,   79 80
Finding a biomarker that could potentially replace invasive methods would surely ease diagnostics. 
While many biomarkers have been found to be associated with CAV none has been established for a 
definite use. Both higher CRP and N-terminal pro-brain natriuretic peptide (NT-pro BNP) levels are 
associated with higher all-cause mortality in HTx patient, but neither predicts CAV development 
specifically.  The von Willebrand factor on the other hand is predictive of the patients with 81
increased risk of CAV.  A promising marker detected recently is microRNA 628-5p (miR-628-5p) 82
that was able to detect CAV with a sensitivity of 72% and a specificity of 83% in advanced CAV 
patients.  83
4.0 Prognosis 
Survival of patients diagnosed with CAV seems to have increased in the transplant era of 2003–
2012 compared to 1994–2002 (2014 ISHLT report).  Lengthened survival can however not be 84
attributed to a substantially improved treatment strategy and prognosis is still quite dim. Although 
the disease generally is slowly progressive the final outcome is devastating, i.e. pump failure or 
malignant arrhythmia resulting in HF and death if re-transplantation is not performed. In a 
multicenter study of 2609 HTx patients, 7% of those with angiographic CAV either died or were re-
transplanted at 5 years. And two thirds (66%) of those with severe CAV (defined as left main 
stenosis >70%, two or more primary vessels stenoses >70%, or branch stenoses >70% in all three 
systems).  In a smaller study of 54 patients overall survival at one, two, and five years was 67%, 85
44%, and 17 % respectively, when stenosis of coronary arteries was defined as ≥40%.  86
5.0 Prevention 
Given the poor prognosis and lack of effective treatment, prevention is the cornerstone of CAV 
management. The standard immunosuppressive management for a cardiac transplant recipient used 
at Rebro University Hospital can be seen in Table 4. Out of these, mammalian target of rapamycin 
(mTOR) inhibitors everolimus and sirolimus have shown the greatest ability to prevent and/or slow 
CAV development. Though, only sirolimus has role in treatment of established CAV at the moment. 
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5.1 mTOR inhibitors  
mTOR inhibitors block the interleukin-2 (IL-2) transduction pathway and hence prevents T- and B- 
cell proliferation. Sirolimus (SRL) may also inhibit SMC proliferation that might be of particular 
importance. Studies shows that SRL in combination with cyclosporine and steroids reduces both 
CAV and grade 3a acute rejection significantly at 2 years in comparison to azathioprine combined 
with the aforementioned drugs.  Everolimus (EVL) also demonstrates the same superiority in 87
comparison to azathioprine.  The downside to mTOR inhibitors is that side effects such as anemia, 88
thrombocytopenia, hyperlipidemia, and renal dysfunction are more frequently seen. They have 
unwanted interaction with calcineurin inhibitors (CNI) in such a way that renal function is 
worsened. Additionally, SRL needs to be avoided in the early post-transplant period because its 
impairment of wound healing.  
Other studies have compared EVL to mycophenolate mofetil (MMF) and cyclosporine. In the one 
trial, a multicenter 24-month study of 721 de novo cardiac transplant recipients, patients where 
randomly assigned to EVL with reduced cyclosporine (to reduce renal dysfunction) or MMF with 
standard-dose cyclosporine. While the EVL regime did reduce CAV incidence it also had higher 
mortality rates at 3 months and at 1 year, leading to suspension of this study arm by the data safety 
monitoring board.  EVL is therefore not recommended for early use after HTx according to the 89
Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration (FDA). 
A Scandinavian study tried an alternative approach by replacing cyclosporine with EVL either 
completely or partly (EVL only or EVL with low dose cyclosporine, both in combination with 
MMF and corticosteroids). Findings proved that EVL prevents CAV independently without 
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Table 4. Immunosuppressive management for HTx recipient at Rebro University Hospital.
first month months 2–6 >6 months
Cyclosporine target level:  
200–250ng/ml
target level:  
150–200ng/ml
target level:  
100–150ng/ml
Tacrolimus target level:  
12–15ng/ml
target level:  
10–15ng/ml
target level:  
5–10ng/ml
Mycophenolate mofetil 1000–1500mg b.i.d
Everolimus target level:  
3–8ng/ml
target level:  
3–8ng/ml
Steroids 0.2mg/kg/day 0.15–0.2mg/kg/day 0.1mg/kg/day
cyclosporine and that renal dysfunction can be avoided. Unfortunately, patient with CNI-free 
therapy experienced almost twice the incidence of biopsy-proven cardiac allograft rejection >grade 
2R compared to those who remained on cyclosporine (10.2% vs. 5.9 percent).  Hence, CNI-free 90
therapy with EVL should be used cautiously and delayed until adequate rejection control is 
obtained. 
5.2 Statins 
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are part of 
standard care of HTx patients even before dyslipidemia develops. Besides improvement of the lipid 
profile statins also lower CRP levels, improve endothelial function, reduced inflammation at the site 
of the coronary plaques, inhibit platelet aggregation, and show anticoagulant effects. ,  All of 91 92
which are very beneficial in CAV prevention, supposedly. Statins improve survival, reduce 
incidence and severity of CAV, and reduce incidence of allograft rejection.  For optimal care it's 93
vital that statin therapy is initiated early. This was demonstrated in a study through adding statin 
therapy to the control arm at 4 years and later reevaluating any potential difference. At 8 years the 
group randomly assigned to the statin group at the very start showed increased survival (89% vs. 
60%) as well as increased vascular benefits.  The main adverse affect of statins is myopathy and 94
there is particularly concern since both cyclosporine and tacrolimus inhibit the enzyme, CYP3A4, 
responsible for metabolizing most statins. Fortunately pravastatin and fluvastatin have other 
metabolic pathways and are safer options for HTx recipients.  95
5.3 Miscellaneous   
Since oxidative stress appears to play a role in CAV pathogenesis is was postulated that antioxidant 
therapy could prevent progression. This was later confirmed by Fang et al, who randomly assigned 
patients to take vitamin C (500 mg twice daily) and E (400 IU twice daily) during the first two (0–
2) post-transplant years. Intimal index had increased by 8% for the placebo group versus 0.8% in 
the treatment group at 1 year.  Another study also found L-arginine therapy to be beneficial. It is 96
though that HTx patient use an excess of endogenous NO to buffer increased vascular oxidant 
stress, and that L-arginine supplementation corrects the NO deficit.   97
Cytomegalovirus prophylaxis, compared to a preemptive approach, is associated with delayed onset 
of CMV infection, lower viral burden, reduced CMV disease/syndrome and less intimal thickening 
at 1 year.  98
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Diltiazem showed promising results in the early 90’s. While the average coronary diameter fell in 
the control group from 2.41 mm at baseline to 2.19 and 2.22 at 1 and 2 years, respectively, it 
remained unchanged for the treatment group.  Limitations to these finding are that this study 99
preceded the statin era and that IVUS wasn’t used to confirm the results. A later multicenter 
retrospective study of 719 patients also refuted the benefits of diltiazem and consequently its use is 
not indicated today.  100
Although the coagulation response of endothelial cells is altered in CAV patients there is no 
evidence that aspirin therapy is beneficial. The high platelet reactivity seen in these patients may 
explain the aspirin resistance.  101
6.0 Treatment 
Once a patient has established CAV very little can be done to prevent progression or cause 
regression. Options are adjusting the immunosuppressive treatment, revascularization therapy such 
as percutaneous intervention (PCI) and coronary artery bypass grafting (CABG), prevention of 
sudden cardiac death with prophylactic implantable cardiac defibrillator (ICD), and ultimately 
retransplantation. Moreover, heart failure should of course be treated with with conventional HF 
medication. 
6.1 Adjusting immunosuppression 
Immunosuppression can be adjusted in two ways in the treatment of CAV. First, because of the 
observed correlation between acute allograft rejection and CAV it’s thought that augmentation 
might be possible. In a study of 76 patients, 22 episodes of vasculopathy was treated with a three 
day methylprednisolone pulse and antithymocyte globulin. Regression was noted in 15 (68%) and 
incidence of regression was 92% if instituted within the first year (versus 40% if instituted after the 
first year).  Despite positive results, augmentation therapy is not routinely used because of the 102
increased risk of infections and malignancy that follows.  
Secondly, sirolimus (SRL) has been evaluated in two reports for treatment of established CAV. One 
of the trials simply added SRL to the regime while the second replaced the CNI (tacrolimus or 
cyclosporine) with SRL. Combined findings from both trials where that SRL has less need for PCI 
& CABG, lower incidence of MI, smaller increase in catheterization score, lower death rate, and 
less increase in mean coronary plaque volume and plaque index. ,  The only and very major 103 104
concern with a CNI-free regime, again, is the potential increased risk of acute rejection. Heart Save 
the Nephron (STN) trial experienced this first hand when they had to terminate their study 
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prematurely, since 4 out of 7 patient randomized to SRL developed a grade IIIA rejection episode. 
These patient were given a CNI-free regime already 12 weeks post-transplant, and risk of rejection 
might be lower as the time from transplant increases. Consensus is that SRL is beneficial in 
treatment of established CAV however questions like ”when to initiate treatment” and ”if to replace 
CNI or not” remain. 
6.2 Revascularization 
Revascularization therapy is considered palliative and is only used in highly selective patients, 
because of the diffuse and distal nature of CAV lesions. PCI has been used in patients with lesions 
limited to only one artery in several studies, yet it remains unproven if the intervention improves 
graft survival. The immediate success rate is very high regardless of type of PCI used, though 
restenosis rate differ significantly. Ballon angioplasty shows an immediate success rate of 92–94% 
and restenosis rate of 20–55% at six to 15 months after the procedure. , , , ,  Bare metal 105 106 107 108 109
stents (BMS) has a slightly better immediate success rate but a significantly lower restenosis rate 
compared to angioplasty (7% vs 39% at three months as well as 34% vs 71% at eight months, 
respectively). ,  However, after 5 years differences seem to abate with reports showing nearly 110 111
identical restenosis rates for both methods.  Although drug eluting stents (DES) are generally 112
recommended over BMS, current studies show conflicting results. , , , ,  Risk of in stent 113 114 115 116 117
restenosis (ISR) is diminished by higher dosage of antiproliferative agents (azathioprine ≥1 mg/kg 
per day or mycophenolate ≥3 g/day) and increased by the presence of anti-HLA antibodies. ,  118 119
On a final note, CABG is also possible. Though, in a report of 12 patients undergoing the procedure 
as much as four patients died perioperatively, raising concerns about high mortality.  120
6.3 Other treatment modalities 
Retransplantation is the last resort when all other options have failed and the only definite 
treatment. With such scarce resources of grafts, patient eligible for a retransplant are part of a highly 
selective and small subgroup (about 3% of all recipients). These patients, typically of young age, 
have an expected survival of 70% and 38% at 1 and 10 years respectively, which is inferior to 
primary transplant recipients. The two most important prognostic factors are etiology of graft failure 
and intertransplant interval between the first and second transplant. Interestingly, CAV has the best 
prognosis while primary graft failure has the worst. Patients with an interval of ≤2 years have a 
survival rate of 60% at 1 year compared to 75% for patient with an interval >2 years. ,  121 122
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Implantable cardioverter-defibrillator (ICD), is recommended as primary prevention in patients at 
risk of sudden cardiac death due to ventricular fibrillation (VF) and ventricular tachycardia (VT). 
Despite recommendations to use ICD in advanced CAV patients, with or without left ventricular 
dysfunction, there is paucity of data to settle its definite role.  123
New strategies are needed to prevent, treat and prolong survival of cardiac transplant patients who 
suffer from CAV. But with such a complex pathogenesis it is difficult to find a target that can 
modulate the vast number of influential factors. A few studies have evaluated high-intensity interval 
training (HIIT) as a preventive factor and found promising results, not only as a protective factor 
but also because its potential to lower burden of anxiety. ,  Experiments on mice and rat models 124 125
have found new potential drugs such as Rho-kinase inhibitor , VEGF inhibitor , complement 126 127
inhibition , anti-OX40L monoclonal antibody  and JAK inhibitor . A lot of research is ongoing 128 129 130
and perhaps one of these new experimental drugs will change the grim outcome of CAV that we 
know today, only time will tell…  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